Back to results

Study of BioNIR Drug Eluting Stent System in Coronary Stenosis (BIONICS)

Primary Purpose

Coronary Artery Stenosis

Status

Completed

Phase

Not Applicable

Locations

International

Study Type

Interventional

Intervention

BioNIR

Resolute

About this trial

This is an interventional treatment trial for Coronary Artery Stenosis focused on measuring more comers, DES, BioNIR, ACS, non ACS, complex lesions

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

Patient with indication for PCI including angina/silent ischemia/NSTEMI/recent STEMI
Non-target vessel PCI allowed prior to randomization depending on time interval and certain conditions
Patient/legal guardian willing & able to provide informed written consent & comply with follow-up visits & testing schedule
Target lesion(s) must be located in native coronary artery/bypass graft conduit w/visually estimated diameter ≥2.5mm to ≤4.25mm.
Complex lesions allowed, including calcified, presence of thrombus, CTO, bifurcation (except as per exclusion criteria #30), ostial RCA, tortuous, bare metal stent restenotic, protected left main, and saphenous vein graft

Exclusion Criteria:

STEMI within 24 hours of init. time of presentation to first treating hospital, or in whom enzyme levels (either CK-MB or Troponin) have not peaked
PCI within 24 hours preceding baseline procedure
Non-target lesion PCI in target vessel within 12 months of baseline procedure
History of stent thrombosis
Cardiogenic shock (persistent hypotension [systolic blood pressure <90mm/Hg for MT 30 min] or requiring pressors/hemodynamic support, including IABP)
Subject is intubated
Known LVEF <30%
Relative/absolute contraindication to DAPT for 12 months (including planned surgeries that cannot be delayed, or subject indicated for chronic oral anticoagulant treatment)
Calculated creatinine clearance <30 mL/min per Cockcroft-Gault equation (<40mL/min for subjects participating in angiographic follow-up sub-study)
Hemoglobin <10g/dL
Platelet count <100,000 cells/mm3 or >700,000 cells/mm3
White blood cell (WBC) count <3,000 cells/mm3
Clinically significant liver disease
Active peptic ulcer/active bleeding from any site
Bleeding from any site within prior 8 wks requiring active medical/surgical attention
If femoral access is planned, significant peripheral arterial disease that precludes safe insertion of 6F sheath
History of bleeding diathesis/coagulopathy/will refuse blood transfusions
Cerebrovascular accident/transient ischemic attack within past 6 months, or any permanent neurologic defect attributed to CVA
Known allergy to study stent components, BioNIR or Resolute
Known allergy to protocol-required concomitant medications: aspirin/DAPT (clopidogrel, prasugrel, ticagrelor)/heparin and bivalirudin/iodinated contrast that cannot be adequately pre-medicated
Any co-morbid condition that may cause non-compliance with protocol (e.g. dementia, substance abuse) /reduced life expectancy to <24 months (e.g. cancer, severe heart failure, severe lung disease)
Patient participating/plans to participate in another investigational drug/device clinical trial that has not reached its primary endpoint
Pregnant/breastfeeding women (women of child-bearing potential must have a negative pregnancy test within 1 wk before treatment)
Women who intend to become pregnant within 12 months after baseline procedure (sexually active women of child-bearing potential must agree to use a reliable method of contraception from time of screening through 12 months post baseline procedure)
Patient has received/is on a waiting list for an organ transplant
Patient receiving/scheduled to receive chemotherapy within 30 days before/any time after the baseline procedure
Patient receiving oral/intravenous immunosuppressive therapy or has known life-limiting immunosuppressive/autoimmune disease (e.g. HIV); corticosteroids are allowed
More than 100mm length of planned stenting in the entire coronary tree
Unprotected left main lesions ≥30%, or planned left main intervention
Ostial LAD/LCX lesions (stenting of any diseased segment within 5mm of the unprotected left main coronary artery)
Bifurcation lesions with planned dual stent implantation
Stenting of lesions due to DES restenosis
Another lesion in a target/non-target vessel (including all side branches) is present that requires/has high probability of requiring PCI within 12 months after baseline procedure

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Active Comparator

Arm Label

BioNIR

Resolute

Arm Description

The BioNIR Ridaforolimus Eluting Coronary Stent System is a single use device/drug combination product comprising: Stent - a mounted Cobalt Chromium (CoCr) alloy based stent Delivery System - Rapid Exchange (RX) Coronary System Polymer matrix coating - Poly n-butyl methacrylate (PBMA) and CarboSil® Ridaforolimus drug - CAS Registry Number: 572924-54-0 The drug Ridaforolimus is utilized on the stent system at a dose of 1.1 μg/mm2 (with a drug load of 100 μg per 2.75/3.00 x 17 mm stent).

The Endeavor Resolute Zotarolimus-Eluting Stent System consists of four subsystems: Endeavor Resolute Stent- a pre-mounted cobalt alloy based stent Delivery system (Rapid Exchange [RX] Coronary System) Polymer system Zotarolimus - drug The Resolute has a nominal drug dose of 1.6µg Zotarolimus per mm2 of the stent surface area.

Outcomes

Primary Outcome Measures

Target Lesion Failure (TLF)

The primary endpoint of TLF at 12 months was defined as the composite of cardiac death, target vessel-related MI, or ischemia-driven TLR.

Secondary Outcome Measures

Device Success

Clinical: Acute secondary endpoint determined at time of baseline procedure

TLF

Clinical secondary endpoint to be evaluated at 30 days, 6 months, and 2, 3, 4 and 5 years, defined as the composite of cardiac death, target vessel-related MI, or ischemia-driven TLR

Major Adverse Cardiac Events

Clinical: MACE; the composite rate of cardiac death, any MI or ischemia-driven TLR

Target Vessel Failure

Clinical: TVF; the composite rate of death, target vessel related MI or ischemia-driven TVR

All Cause Mortality

Clinical: The number of patients who die from all causes

Cardiac Death

Clinical: The number of patients who die of cardiac-related causes

Myocardial Infarction

Clinical: The number of patients who suffer a myocardial infarction.

Target Vessel Related MI

Clinical: The number of patients who suffer a MI that is related to the target vessel of the procedure.

Ischemia Driven TLR

Clinical:

Ischemia Driven TVR

Clinical:

Stent Thrombosis

Clinical: ARC definite and probable

Angiographic Sub-Study: In-stent and In-segment Late Loss

Secondary Endpoint for angiographic in-stent and in-segment late loss

IVUS Sub-Study: In-stent Percent Neointimal Hyperplasia

IVUS: In-stent percent neointimal hyperplasia

IVUS Sub-Study: Stent Mal-apposition

IVUS Sub-Study: Stent mal-apposition

Lesion Success

Measures whether the lesion was successfully treated.

Procedure Success

Acute clinical endpoint: The success of the procedure as determined at time of baseline procedure

Full Information

NCT ID

NCT01995487

First Posted

November 12, 2013

Last Updated

October 1, 2023

Sponsor

Medinol Ltd.

1. Study Identification

Unique Protocol Identification Number

NCT01995487

Brief Title

Study of BioNIR Drug Eluting Stent System in Coronary Stenosis

Acronym

BIONICS

Official Title

BioNIR Ridaforolimus Eluting Coronary Stent System (BioNIR) In Coronary Stenosis Trial

Study Type

Interventional

2. Study Status

Record Verification Date

October 2023

Overall Recruitment Status

Completed

Study Start Date

January 2014 (undefined)

Primary Completion Date

August 28, 2016 (Actual)

Study Completion Date

November 30, 2020 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title

Sponsor

Name of the Sponsor

Medinol Ltd.

4. Oversight

Data Monitoring Committee

Yes

5. Study Description

Brief Summary

The BioNIR study aims to show that the BioNIR ridaforolimus eluting stent is non-inferior to the Resolute zotarolimus-eluting stent for the primary clinical endpoint of target lesion failure (TLF) at 12 months; that it is non-inferior to the Resolute for the secondary endpoint of angiographic in-stent late loss at 13 months; and that it is more cost-effective.

Detailed Description

The BioNIR is a prospective, multi-center, single-blind, two-arm, randomized clinical trial. The population will consist of subjects undergoing PCI for angina (stable or unstable), silent ischemia, NSTEMI, and recent STEMI. Complex lesions are allowed. There is no limit to the number of lesions per vessel or individual lesion length; however, the total planned stenting in the coronary tree cannot exceed 100mm. Randomization will be stratified by the presence of medically treated diabetes vs. no medically treated diabetes, acute coronary syndrome (ACS) vs. non-ACS, and by site. Lesions planned to be treated must be declared and recorded at time of randomization. Planned staged procedures, if necessary, must be declared immediately post procedure. Clinical follow-up will be performed at 30 days, 6 months, and 1, 2, 3, 4, and 5 years post randomization. 200 patients at participating North American sites will be consented for planned angiographic follow-up at 13 months after enrollment, with 100 of these patients consented to undergo planned IVUS at baseline and at 13 months following randomization. The primary endpoint is Target Lesion Failure (TLF) at 12 months, defined as the composite of cardiac death, target vessel-related myocardial infarction, or ischemia-driven target lesion revascularization. Clinical Secondary Endpoints to be evaluated at 30 days, 6 months, and 1, 2, 3, 4 and 5, except as noted: Device, Lesion, and Procedure Success at time of baseline procedure TLF at 30 days, 6 months, and 2, 3, 4 and 5 years defined as the composite of cardiac death, target vessel-related MI, or ischemia-driven TLR. Major adverse cardiac events (MACE; the composite rate of cardiac death, any MI or ischemia-driven TLR) Target vessel failure (TVF; the composite rate of death, target vessel related MI or ischemia-driven TVR) All-cause mortality Cardiac death Myocardial Infarction Target Vessel Related MI Ischemia-driven TLR Ischemia-driven TVR Stent Thrombosis (ARC definite and probable) Angiographic Sub-Study Secondary Endpoint to be evaluated at 13 months: • Angiographic in-stent and in-segment late loss IVUS Sub-Study Secondary Endpoint to be evaluated at 13 months: In-stent percent neointimal hyperplasia Stent mal-apposition A key component of this trial will be a prospective assessment of health care resource utilization, costs and cost effectiveness. A separate cost effectiveness assessment plan describes the data collection and analysis. Sample Size Consideration: From recent US trials of best in class DES (Xience V, Promus Element and Resolute), the 1-year TLF rate in patients with non-complex lesions not undergoing routine angiographic follow-up is approximately 3.8%. Using the assumption of the more-comers' design, the 1-year event rate will be conservatively increased by 50% (assuming enrollment rate for complex patients/lesions is 50% with double the standard event rate) - thus 5.8%. Therefore, with a one-sided 95% upper bound of the confidence interval of 3.3% (a relative 57% margin) and 1:1 randomization, enrolling 1810 patients (905 per group) provides 90% power to demonstrate non-inferiority. Assuming 95% follow-up rate at 1 year, approximately 1906 patients will be enrolled (953 in each group).

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study

Coronary Artery Stenosis

Keywords

more comers, DES, BioNIR, ACS, non ACS, complex lesions

7. Study Design

Primary Purpose

Treatment

Study Phase

Not Applicable

Interventional Study Model

Parallel Assignment

Model Description

This is a Drug-Device combination Product.

Masking

Participant

Allocation

Randomized

Enrollment

1919 (Actual)

8. Arms, Groups, and Interventions

Arm Title

BioNIR

Arm Type

Experimental

Arm Description

Arm Title

Resolute

Arm Type

Active Comparator

Arm Description

Intervention Type

Device

Intervention Name(s)

BioNIR

Intervention Description

drug-eluting stent

Intervention Type

Device

Intervention Name(s)

Resolute

Intervention Description

drug-eluting stent

Primary Outcome Measure Information:

Title

Target Lesion Failure (TLF)

Description

The primary endpoint of TLF at 12 months was defined as the composite of cardiac death, target vessel-related MI, or ischemia-driven TLR.

Time Frame

12 months

Secondary Outcome Measure Information:

Title

Device Success

Description

Clinical: Acute secondary endpoint determined at time of baseline procedure

Time Frame

Determined at time of baseline procedure

Title

TLF

Description

Clinical secondary endpoint to be evaluated at 30 days, 6 months, and 2, 3, 4 and 5 years, defined as the composite of cardiac death, target vessel-related MI, or ischemia-driven TLR

Time Frame